 from the DREAM,765 EVAR 1,682 OVER,766 and
ACE362 randomized trials showed EVAR to be costeffective on the basis of the OVER trial data, but no difference in lifetime cost-effectiveness was derived from data
generated by the European trials, suggesting that results
may not be generalizable among different countries.767
EVAR also does not appear to be cost-effective for treatment of complicated aneurysms.